ArticleBMC ophthalmology2026
Clinical and refractive outcomes of bilateral enhanced monofocal intraocular lens implantation with targeted mini-monovision.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate visual and refractive outcomes, as well as patient satisfaction after bilateral implantation of an enhanced monofocal intraocular lens (IOL) with targeted mini-monovision.
methodsWe retrospectively reviewed the medical records of patients who underwent bilateral RayOne EMV IOL implantation during cataract surgery with targeted mini-monovision (-0.50 diopters [D] in the non-dominant eye). Patients' monocular and binocular uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), uncorrected intermediate visual acuity (UIVA), distance-corrected intermediate visual acuity (DCIVA), and manifest refraction were assessed at the 1st and 6th months postoperatively. Binocular uncorrected and corrected near visual acuities, defocus curves, contrast sensitivity, spectacle independence, dysphotopsia, and patient-reported outcomes were evaluated at Month 6. Patient-reported visual function and satisfaction were assessed using the CatQuest-9SF questionnaire, while spectacle independence and dysphotopsia were evaluated separately using study-specific questions.
resultsFifty eyes of 25 patients were included. Mean age was 63.64 ± 10.53 years (range: 29-78 years), and the mean follow-up period was 14.52 ± 5.6 months (range: 6-24 months). At 6 months postoperatively, the mean spherical equivalent in dominant eyes was - 0.37 ± 0.29 D (range: -1.00 to + 0.38 D), whereas in non-dominant eyes, it was - 0.78 ± 0.46 D (range: -1.75 to + 0.25 D). The mean binocular UDVA was 0.02 ± 0.03 logMAR (range: 0.00- 0.10 logMAR), while binocular UIVA acuity was 0.21 ± 0.09 logMAR (range: 0.00- 0.40 logMAR) at month 6. Mean binocular uncorrected near visual acuity (UNVA) at 6 months was 0.24 ± 0.12 logMAR, whereas corrected near visual acuity (CNVA) was 0.14 ± 0.08 logMAR (P < 0.001). Binocular UDVA was 0.04 logMAR or better in 96% of patients, UIVA was 0.20 logMAR or better in 64%, and uncorrected near visual acuity was 0.3 logMAR or better in 80% of patients. All patients were spectacle independent for distance and intermediate vision; 10/25 patients (40%) were also spectacle independent for near vision, whereas 15/25 (60%) required a near addition. Twenty-four patients (96%) reported being very satisfied with their vision.
conclusionBilateral implantation of an enhanced monofocal IOL with targeted mini-monovision was associated with excellent visual outcomes at intermediate and distance vision with a high level of satisfaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.